TMC207 becomes bedaquiline, a new anti-TB drug

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Almeida da Silva PE, Palomino JC. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs. J. Antimicrob. Chemother.66(7),1417–1430 (2011).▪ Presents a recent update on the molecular mechanisms of drug resistance in TB.
  Medline CASGoogle Scholar
• 2  Udwadia ZF, Amale RA, Ajbani KK, Rodrigues C. Totally drug-resistant tuberculosis in India. Clin. Infect. Dis.54(4),579–581 (2012).
  MedlineGoogle Scholar
• 3  Migliori GB, Centis R, D’Ambrosio L et al. Totally drug-resistant and extremely drug-resistant tuberculosis: the same disease? Clin. Infect. Dis.54(9),1379–1380 (2012).
  Medline CASGoogle Scholar
• 4  WHO. Treatment of Tuberculosis Guidelines (4th Edition). WHO, Geneva, Switzerland (2009).
  Google Scholar
• 5  Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr. Opin. Pulm. Med.16(3),186–193 (2010).
  Medline CASGoogle Scholar
• 6  Palomino JC, Martin A. Is repositioning of drugs a viable alternative in the treatment of tuberculosis? J. Antimicrob. Chemother.68(2),275–283 (2013).
  Medline CASGoogle Scholar
• 7  Grosset JH, Singer TG, Bishai WR. New drugs for the treatment of tuberculosis: hope and reality. Int. J. Tuberc. Lung Dis.16(8),1005–1014 (2012).▪▪ Concise and up-to-date review of the new drugs currently in development for the treatment of TB.
  Medline CASGoogle Scholar
• 8  Matsumoto M, Hashizume H, Tomishige T et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med.3(11),e466 (2006).
  MedlineGoogle Scholar
• 9  Diacon AH, Dawson R, Hanekom M et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int. J. Tuberc. Lung Dis.15(7),949–954 (2011).
  Medline CASGoogle Scholar
• 10  Gler MT, Skripconoka V, Sanchez-Garavito E et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N. Engl. J. Med.366(23),2151–2160 (2012).
  Medline CASGoogle Scholar
• 11  Stover CK, Warrener P, VanDevanter DR et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature405(6789),962–966 (2000).
  Medline CASGoogle Scholar
• 12  Diacon AH, Dawson R, Hanekom M et al. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob. Agents Chemother.53(8),3402–3407 (2010).
  Google Scholar
• 13  Diacon AH, Dawson R, du Bois J et al. Phase II dose-ranging trial of the early bactericidal activity of PA-824. Antimicrob. Agents Chemother.56(6),3027–3231 (2012).
  Medline CASGoogle Scholar
• 14  Villemagne B, Crauste C, Flipo M, Baulard AR, Déprez B, Willand N. Tuberculosis: the drug development pipeline at a glance. Eur. J. Med. Chem.51,1–16 (2012).▪ Describes the current TB drug development pipeline.
  Medline CASGoogle Scholar
• 15  Cheepsattayakorn A, Cheepsattayakorn R. Novel compounds and drugs and recent patents in treating multidrug-resistant and extensively drug-resistant tuberculosis. Recent Pat. Antiinfect. Drug Discov.7(2),141–156 (2012).
  Medline CASGoogle Scholar
• 16  Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP synthase inhibitor. Antimicrob. Agents Chemother.51(11),4202–4204 (2007).
  Medline CASGoogle Scholar
• 17  Andries K, Verhasselt P, Guillemont J et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science307(5707),223–227 (2005).▪▪ Key publication describing the discovery and initial evaluation of bedaquiline against Mycobacterium tuberculosis.
  Medline CASGoogle Scholar
• 18  Lenaerts AJ, Hoff D, Aly S et al. Location of persisting Mycobacteria in a guinea pig model of tuberculosis revealed by r207910. Antimicrob. Agents Chemother.51(9),3338–3345 (2007).
  Medline CASGoogle Scholar
• 19  Lounis N, Guillemont J, Veziris N, Koul A, Jarlier V, Andries K. R207910 (TMC207): un nouvel antibiotique pour le traitement de la tuberculose. Med. Mal. Infect.40(7),383–390 (2010).
  Medline CASGoogle Scholar
• 20  Gaurrand S, Desjardins S, Meyer C et al. Conformational analysis of r207910, a new drug candidate for the treatment of tuberculosis, by a combined NMR and molecular modeling approach. Chem. Biol. Drug Des.68(2),77–84 (2006).
  Medline CASGoogle Scholar
• 21  Petit S, Coquerel G, Meyer C, Guillemont J. Absolute configuration and structural features of R207910, a novel antituberculosis agent. J. Mol. Struct.837(1–3),252–256 (2007).
  CASGoogle Scholar
• 22  Koul A, Dendouga N, Vergauwen K et al. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol.3(6),323–324 (2007).
  Medline CASGoogle Scholar
• 23  Haagsma AC, Abdillahi-Ibrahim R, Wagner MJ et al. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob. Agents Chemother.53(3),1290–1292 (2009).
  Medline CASGoogle Scholar
• 24  Petrella S, Cambau E, Chauffour A et al. Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria. Antimicrob. Agents Chemother.50(8),2853–2856 (2006).
  Medline CASGoogle Scholar
• 25  Segala E, Sougakoff W, Nevejans-Chauffour A, Jarlier V, Petrella S. New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure. Antimicrob. Agents Chemother.56(5),2326–2634 (2012).
  Medline CASGoogle Scholar
• 26  Huitric E, Verhasselt P, Koul A, Andries K, Hoffner S, Andersson DI. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob. Agents Chemother.54(3),1022–1028 (2010).
  Medline CASGoogle Scholar
• 27  Ji B, Lefrançois S, Robert J, Chauffour A, Truffot C, Jarlier V. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob. Agents Chemother.50(6),1921–1926 (2006).
  Medline CASGoogle Scholar
• 28  Lechartier B, Hartkoorn RC, Cole ST. In vitro combination studies of Benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother.56(11),5790–5793 (2012).
  Medline CASGoogle Scholar
• 29  Reddy VM, Einck L, Andries K, Nacy CA. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob. Agents Chemother.54(7),2840–2846 (2010).
  Medline CASGoogle Scholar
• 30  Rustomjee R, Diacon AH, Allen J et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother.52(8),2831–2835 (2008).▪ Describes the bactericidal activity of bedaquiline in TB patients.
  Medline CASGoogle Scholar
• 31  Diacon AH, Dawson R, Von Groote-Bidlingmaier FT et al. A randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob. Agents Chemother.57(5),2199–2203 (2013).
  Medline CASGoogle Scholar
• 32  Diacon AH, Pym A, Grobusch M et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N. Engl. J. Med.360(23),2397–2405 (2009).▪▪ Key publication describing the results of a Phase II clinical trial of bedaquiline.
  Medline CASGoogle Scholar
• 33  Diacon AH, Donald PR, Pym A et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob. Agents Chemother.56(6),3271–3276 (2012).
  Medline CASGoogle Scholar
• 34  Roehr B. FDA approves rifapentine for the treatment of pulmonary tuberculosis. J. Int. Assoc. Physicians AIDS Care4(8),19–25 (1998).
  Medline CASGoogle Scholar
• 35  Dorman SE, Goldberg S, Stout JE et al. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J. Infect. Dis.206(7),1030–1040 (2012).
  Medline CASGoogle Scholar
• 36  Lounis N, Gevers T, Van Den Berg J, Andries K. Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob. Agents Chemother.52(10),3568–3572 (2008).
  Medline CASGoogle Scholar
• 37  Dooley KE, Park JG, Swindells S et al. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J. Acquir. Immune Defic. Syndr.59(5),455–462 (2012).
  Medline CASGoogle Scholar
• 38  Diacon AH, Dawson R, von Groote-Bidlingmaier F et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet380(9846),986–993 (2012).▪ Describes the results of the first bactericidal activity study that tested new drug combinations for TB.
  Medline CASGoogle Scholar
• 39  Shang S, Shanley CA, Caraway ML et al. Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. Antimicrob. Agents Chemother.55(1),124–131 (2011).
  Medline CASGoogle Scholar
• 101  WHO. Global tuberculosis report 2012. www.who.int/tb/publications/global_report/gtbr12_main.pdf
  Google Scholar
• 102  A study to evaluate the efficacy and safety of TMC207 in patients with pulmonary infection with multi-drug resistant Mycobacterium tuberculosis. www.clinicaltrials.gov/ct2/show/NCT01600963
  Google Scholar
• 103  Anti-Infective Drugs Advisory Committee Meeting Briefing Document. TMC207 (bedaquiline). www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM329260.pdf
  Google Scholar
• 104  ClinicalTrials.gov. http://clinicaltrials.gov
  Google Scholar
• 105  TMC207-TiDP13-C117: interaction study in human immunodeficiency virus-type 1 (HIV-1) infected patients with nevirapine (NVP). www.clinicaltrials.gov/ct2/show/NCT00910806
  Google Scholar
• 106  Treatment of patients with MDR-TB. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM329260.pdf
  Google Scholar
• 107  TMC207-TiDP13-C110: interaction study with lopinavir/ritonavir in healthy volunteer. www.clinicaltrials.gov/ct2/show/NCT00828529
  Google Scholar
• 108  Summary Minutes of the Anti-Infective Drugs Advisory Committee, 3 June 2009. www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM183845.pdf
  Google Scholar